Biomarker Discovery Center
Established at the NJISA in late 2012, the Biomarker Discovery Center builds on the recent discoveries by NJISA researchers that could significantly change the diagnosis and treatment of a number of diseases. The Center is under the direction of Robert Nagele, PhD, who has received national recognition for his published research into the use of blood-borne biomarkers to diagnose early stages of Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis.
Scientific and medical interest in biomarkers has intensified in recent years. The need for early diagnostics that are accurate, relatively non-invasive and cost effective is critical and Dr. Nagele’s published research as illustrated some exciting results, including:
In January 2013, the Biomarker Discovery Center was awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment caused by early-stage Alzheimer’s disease.
Currently, the lab is funded by the National Institutes of Health to carry out a large-scale validation study of the utility of the Alzheimer’s disease biomarkers and to pursue new blood-based biomarkers for very early (preclinical) detection of this devastating disease.
Recent Publications by Robert Nagele, PhD
Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG. (2013) Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One, 8(4):e60726. doi:10.1371/journal.pone.0060726.
Acharya NK, Nagele EP, Han M, and Nagele RG. (2013) Autoantibodies: Double Agents in Human Disease. Science Translational Medicine, 5, 186fs19.
Acharya NK, Goldwaser EL, Forsberg MM, Godsey GA, Johnson CA, Sarkar A, DeMarshall C, Kosciuk MC, Dash JM, Hale CP, Leonard D, Appelt DM, and Nagele RG. (2015) Sevoflurane and Isoflurane induce structural changes in brain vascular endothelial cells and increase blood-brain barrier permeability: Possible link to postoperative delirium and cognitive decline. Brain Research, Brain Res 2015 May 8. Epub 2015 May 8.
DeMarshall C, Abhirup Sarkar, Eric P. Nagele, Eric Goldwaser, George Godsey, Nimish K. Acharya and Robert G. Nagele (2015) Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases. Int. Rev Neurobiol. 2015;122:1-51. doi: 10.1016/bs.irn.2015.05.005. 2015 Jun 19. (Invited Review).
DeMarshall CA, Han M, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL, Kosciuk M, Thayasivam U, Belinka B, Nagele RG and the Parkinson’s Study Group Investigators (2015) Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson’s disease. Immunol Lett. 168(1):80-88. PMID: 26386375.
DeMarshall CA, Nagele EP, Sarkar A, et al. Detection of Alzheimer’s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2016;3:51-62. doi:10.1016/j.dadm.2016.03.002.
DeMarshall C, EL Goldwaser, A Sarkar, GA Godsey, NK Acharya, U Thayasivam, BA Belinkaf, and RG. Nagele. (2017) Autoantibodies as diagnostic biomarkers for the detection and subtyping of Multiple Sclerosis. Journal of Neuroimmunology 309:51-57. doi: 10.1016/j.jneuroim.2017.05.010. Epub 2017 May 19.PMID:28601288